Comprehensive Study of Social Representation of Platelet Transfusion in Patients Followed for Advanced Hematological Malignancies (R-PLQ)

NCT ID: NCT03806712

Last Updated: 2019-07-25

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 45 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2019-04-01
• Study Completion Date: 2019-07-22

Brief Summary

Limited data is available for end of life care in hematologic malignancies, moreover with thrombocytopenic patients. Thrombopenia is a frequent complication, specific of bone marrow involvement in those diseases or its treatments. Yet, a few studies was interested in, whereas platelet transfusion is the only treatment indicated. As it represent a scarce, limited resource, the ethical principles are in conflict in this setting and there's a lack of recommendation. The final decision is take by the clinician and his patient, but no study exist in representation of the two parts. We provide a qualitative study to understand what this decision is made of.

Conditions

Platelet Transfusion; Hematological Malignancy; Palliative Care

Study Design

• Observational Model Type: OTHER
• Study Time Perspective: PROSPECTIVE

Study Groups

patient

patient with advanced, non curative hematological malignancies multi method questionary, at least 1 hour per patient

multi method questionary (developped by De Rosa, in 1995 and 2014)

Intervention Type: OTHER

questions from an association network according to the subject and the grounded theorise (Glasser and Strauss)

hematologist

medical practitioner of platelet transfusion multi method questionary, at least 1 hour per hematologist

multi method questionary (developped by De Rosa, in 1995 and 2014)

Intervention Type: OTHER

questions from an association network according to the subject and the grounded theorise (Glasser and Strauss)

Nurses

nurses working in hematology, practicing platelet transfusion multi method questionary, at least 1 hour per nurse

multi method questionary (developped by De Rosa, in 1995 and 2014)

Intervention Type: OTHER

questions from an association network according to the subject and the grounded theorise (Glasser and Strauss)

Interventions

multi method questionary (developped by De Rosa, in 1995 and 2014)

questions from an association network according to the subject and the grounded theorise (Glasser and Strauss)

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• major patient
• patient with advanced hematological malignancies
• patient transfused in platelet regularly (3 time at least in last month)
• medical practioner, hematologist, prescribing platelet transfusion at least one per week.
• nurse working in hematology, practicing platelet transfusion at lest one peer week.

Exclusion Criteria

• minor patient
• non communicant patient
• non transfused platelet patient
• non voluntary patient or hematologist or nurses
• non graduated hematologist

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 100 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Centre Hospitalier Universitaire de Besancon

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Moracchini

Besançon, , France

Countries

France

References

McGrath P, Leahy M. Catastrophic bleeds during end-of-life care in haematology: controversies from Australian research. Support Care Cancer. 2009 May;17(5):527-37. doi: 10.1007/s00520-008-0506-1. Epub 2008 Sep 23.

Reference Type: BACKGROUND

PMID: 18810505 (View on PubMed)

McGrath P, Holewa H. Special considerations for haematology patients in relation to end-of-life care: Australian findings. Eur J Cancer Care (Engl). 2007 Mar;16(2):164-71. doi: 10.1111/j.1365-2354.2006.00745.x.

Reference Type: BACKGROUND

PMID: 17371426 (View on PubMed)

Jeoffrion C, Dupont P, Tripodi D, Roland-Levy C. [Social representations of illness: Comparison of "expert" knowledge and "naive" knowledge]. Encephale. 2016 Jun;42(3):226-33. doi: 10.1016/j.encep.2015.12.007. Epub 2016 Jan 12. French.

Reference Type: BACKGROUND

PMID: 26796561 (View on PubMed)

Other Identifiers

P/2019/413

Identifier Type: -

Identifier Source: org_study_id